Market Closed -
Nasdaq
16:30:01 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
3.72
USD
|
+1.92%
|
|
-1.59%
|
+40.38%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,183
|
572.9
|
148.4
|
210.2
|
-
|
-
|
Enterprise Value (EV)
1 |
884
|
242.5
|
148.4
|
-20.74
|
42.46
|
210.2
|
P/E ratio
|
-27.8
x
|
-9
x
|
-2.23
x
|
-2.94
x
|
-2.55
x
|
-2.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-24,759,117
x
|
-3,609,892
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
55,232
|
55,841
|
56,000
|
56,495
|
-
|
-
|
Reference price
2 |
21.41
|
10.26
|
2.650
|
3.720
|
3.720
|
3.720
|
Announcement Date
|
22-03-10
|
23-03-14
|
24-03-19
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-35.7
|
-67.19
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-35.83
|
-67.59
|
-78.19
|
-76.31
|
-92.64
|
-103.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-35.53
|
-63.31
|
-66.86
|
-87.51
|
-105.7
|
-116.2
|
Net income
1 |
-8.28
|
-35.53
|
-63.31
|
-66.86
|
-73.11
|
-87.78
|
-116.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5216
|
-0.7700
|
-1.140
|
-1.190
|
-1.265
|
-1.460
|
-1.560
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-05
|
22-03-10
|
23-03-14
|
24-03-19
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.34
|
-11.13
|
-13.37
|
-15.64
|
-19.19
|
-19.39
|
-21.65
|
-22.6
|
-18.82
|
-15.12
|
-16.91
|
-18.33
|
-19.72
|
-21.35
|
-25.96
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.32
|
-11.06
|
-13.26
|
-15
|
-17.7
|
-17.34
|
-19.29
|
-19.94
|
-15.79
|
-11.84
|
-17.94
|
-20.63
|
-23.24
|
-25.7
|
-25.96
|
Net income
1 |
-11.32
|
-11.06
|
-13.26
|
-15
|
-17.7
|
-17.34
|
-19.29
|
-19.94
|
-15.79
|
-11.84
|
-16.07
|
-17.57
|
-19.02
|
-20.45
|
-25.96
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2100
|
-0.2000
|
-0.2400
|
-0.2700
|
-0.3200
|
-0.3100
|
-0.3500
|
-0.3600
|
-0.2800
|
-0.2100
|
-0.2800
|
-0.3050
|
-0.3250
|
-0.3500
|
-0.4300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-09
|
22-03-10
|
22-05-09
|
22-08-08
|
22-11-03
|
23-03-14
|
23-05-09
|
23-08-14
|
23-11-13
|
24-03-19
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
299
|
330
|
-
|
231
|
168
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-05
|
22-03-10
|
23-03-14
|
24-03-19
|
-
|
-
|
-
|
Last Close Price
3.72
USD Average target price
4.667
USD Spread / Average Target +25.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.38% | 210M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|